Wagner Quintilio

Papers

Total Citations

H-Index

About

Wagner Quintilio is a distinguished biotechnologist whose research centers on the development and characterization of monoclonal antibodies for therapeutic applications, with a particular focus on biosimilars and cell line engineering. His most-cited work, a 2018 study on a novel Chinese hamster ovary (CHO)-derived cell line expressing an anti-TNFα monoclonal antibody with biosimilar potential, has garnered 5 citations and underscores his expertise in optimizing mammalian cell expression systems for cost-effective biologic production. Quintilio’s contributions are pivotal in advancing the accessibility of biopharmaceuticals, particularly for inflammatory diseases like rheumatoid arthritis, by demonstrating the feasibility of generating high-quality biosimilar candidates through innovative cell line design. His work bridges fundamental cell biology and translational medicine, offering scalable solutions for global health challenges. Beyond this flagship study, Quintilio’s research portfolio reflects a commitment to refining antibody engineering and production processes, making him a key figure in the biopharmaceutical landscape. His achievements highlight the critical role of CHO cell platforms in reducing drug costs and improving patient access to life-saving therapies.